1059548-86-5

Upstream product

• 1094358-13-0 Methyl 3-fluoro-4-[2-(4-methylpiperazin-1-yl)-thiazol-4-yl]benzoate 

Downstream Products

• 1059549-30-2 N-[1(S)-((3aS,6aS)-6(R)-azido-3,3-dimethoxyhexahydrofuro[3,2-b]pyrrole-4-carbonyl)-3-fluoro-3-methylbutyl]-3-fluoro-4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide 
• 1059549-18-6 N-[1(S)-((3aS,6aS)-6(R)-azido-3,3-dimethoxyhexahydrofuro[3,2-b]pyrrole-4-carbonyl)-3-methylbutyl]-3-fluoro-4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide 
• 1219683-43-8 C₃₁H₄₀FN₅O₅S 

Relevant academic research and scientific papers

PROTEASE INHIBITORS

Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one

Cysteine Protease Inhibitors

Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl- moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

PROTEASE INHIBITORS

Compounds of the formula (II): wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or fluoro; R4 is C1-C6alkyl; E is a bond or thiazolyl, optionally substituted with methyl or fluoro; n is 0 or 1; or a pharmaceutically acceptable salt, N-oxide or hydrate thereof; have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsinK, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.